Characterizing LVV stability just got a whole lot easier.
As a developer of genetic therapies, do you find yourself struggling with the complexity of lentiviral vectors (LVV)?
If so, you’re not alone. Compared to protein biologics, LVVs can be more difficult and expensive to manufacture. The scarcity of LVV material also makes scale-up difficult and adds additional complexity when qualifying subvisible particles, the most indicative critical quality attribute for biologic stability.
But what if there was a way to overcome these challenges?
Halo Labs’ latest application note demonstrates how Aura GT can quantitate and characterize visible and subvisible particles with only 5 ÂµL of sample using Backgrounded Membrane Imaging (BMI) as well as identify the biological and chemical nature of LVV aggregates with Fluorescence Membrane Microscopy (FMM). Gene therapy developers can now begin early stage development characterization of their candidates developing better formulations for drug stability and purity ensuring efficacy and patient safety.